Titan Pharmaceuticals (TTNP) Competitors $3.46 -0.38 (-9.90%) Closing price 03:59 PM EasternExtended Trading$3.52 +0.06 (+1.73%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends TTNP vs. CLRB, BCLI, TSBX, BLRX, JAGX, MBIO, EYEN, AWH, PMCB, and PHXMShould you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Cellectar Biosciences (CLRB), Brainstorm Cell Therapeutics (BCLI), Turnstone Biologics (TSBX), BioLineRx (BLRX), Jaguar Health (JAGX), Mustang Bio (MBIO), Eyenovia (EYEN), Aspira Women's Health (AWH), PharmaCyte Biotech (PMCB), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry. Titan Pharmaceuticals vs. Cellectar Biosciences Brainstorm Cell Therapeutics Turnstone Biologics BioLineRx Jaguar Health Mustang Bio Eyenovia Aspira Women's Health PharmaCyte Biotech PHAXIAM Therapeutics Titan Pharmaceuticals (NASDAQ:TTNP) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking. Which has more risk & volatility, TTNP or CLRB? Titan Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Does the media prefer TTNP or CLRB? In the previous week, Titan Pharmaceuticals and Titan Pharmaceuticals both had 1 articles in the media. Cellectar Biosciences' average media sentiment score of 0.55 beat Titan Pharmaceuticals' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Titan Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, TTNP or CLRB? Titan Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTitan Pharmaceuticals$180K17.81-$5.57MN/AN/ACellectar BiosciencesN/AN/A-$42.77M-$1.72-0.14 Is TTNP or CLRB more profitable? Cellectar Biosciences' return on equity of 0.00% beat Titan Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Titan PharmaceuticalsN/A -118.01% -103.79% Cellectar Biosciences N/A N/A -191.22% Do analysts rate TTNP or CLRB? Cellectar Biosciences has a consensus price target of $17.67, suggesting a potential upside of 7,261.11%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Titan Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cellectar Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals hold more shares of TTNP or CLRB? 31.5% of Titan Pharmaceuticals shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 24.9% of Titan Pharmaceuticals shares are held by company insiders. Comparatively, 3.7% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in TTNP or CLRB? Titan Pharmaceuticals received 92 more outperform votes than Cellectar Biosciences when rated by MarketBeat users. However, 55.35% of users gave Cellectar Biosciences an outperform vote while only 54.12% of users gave Titan Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTitan PharmaceuticalsOutperform Votes33554.12% Underperform Votes28445.88% Cellectar BiosciencesOutperform Votes24355.35% Underperform Votes19644.65% SummaryTitan Pharmaceuticals beats Cellectar Biosciences on 7 of the 13 factors compared between the two stocks. Get Titan Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTNP vs. The Competition Export to ExcelMetricTitan PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.13M$2.99B$5.37B$9.09BDividend YieldN/A1.89%5.37%4.00%P/E RatioN/A44.7186.7617.45Price / Sales17.81292.961,278.6077.80Price / CashN/A189.5236.6032.90Price / Book0.403.974.924.62Net Income-$5.57M-$40.99M$117.96M$224.76M7 Day Performance10.09%2.73%2.19%2.84%1 Month Performance4.23%0.10%3.21%4.81%1 Year Performance-42.72%-0.75%26.71%21.17% Titan Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTNPTitan Pharmaceuticals0.5318 of 5 stars$3.46-9.9%N/A-37.6%$3.15M$180,000.000.0010Analyst ForecastNews CoverageHigh Trading VolumeCLRBCellectar Biosciences2.8478 of 5 stars$0.28-0.2%$17.67+6,169.2%-93.0%$11.63MN/A-0.1610Analyst ForecastHigh Trading VolumeBCLIBrainstorm Cell Therapeutics4.5373 of 5 stars$2.02flat$30.00+1,385.1%-55.1%$11.52MN/A-0.4240Analyst UpgradeNews CoverageGap UpTSBXTurnstone Biologics3.0592 of 5 stars$0.48-0.2%$2.13+343.6%-77.0%$11.08M$19.31M-0.1582News CoverageBLRXBioLineRx2.9691 of 5 stars$0.14-3.8%$9.00+6,450.2%-92.5%$10.98M$21.99M-0.6240Analyst ForecastStock SplitNews CoverageGap UpJAGXJaguar Health0.5596 of 5 stars$0.93-7.4%N/A-86.1%$10.93M$10.48M0.0050MBIOMustang Bio2.6054 of 5 stars$0.22-12.7%$2.00+793.3%-91.8%$10.70MN/A-0.14100Stock SplitGap DownEYENEyenovia2.4598 of 5 stars$0.10-11.1%$2.00+1,983.3%-95.9%$10.70M$31,832.00-0.1340Gap DownAWHAspira Women's Health2.4734 of 5 stars$0.64+1.4%$4.40+587.6%-88.8%$10.67M$8.96M-0.53110Positive NewsGap UpPMCBPharmaCyte BiotechN/A$1.52+0.0%N/A-28.7%$10.59MN/A2.872PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049 Related Companies and Tools Related Companies Cellectar Biosciences Alternatives Brainstorm Cell Therapeutics Alternatives Turnstone Biologics Alternatives BioLineRx Alternatives Jaguar Health Alternatives Mustang Bio Alternatives Eyenovia Alternatives Aspira Women's Health Alternatives PharmaCyte Biotech Alternatives PHAXIAM Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TTNP) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
